Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (Nasdaq: MOVE), operating as Movano Health, is a health-focused technology company dedicated to revolutionizing the way we manage and monitor our health metrics. Founded in 2018 and headquartered in Pleasanton, California, Movano is committed to developing healthcare solutions that bring medical-grade, high-quality data to consumer health devices. The company's flagship product, the Evie Ring, is a wearable designed specifically for women to track a comprehensive array of health metrics including resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, and skin temperature variability. It also monitors period and ovulation tracking, menstrual symptom tracking, steps, active minutes, calories burned, sleep stages and duration, and mood tracking.
Movano Health has made significant strides in advancing its Evie Ring technology, as evidenced by a recent hypoxia trial conducted in collaboration with the University of California, San Francisco (UCSF). The study confirmed that the accuracy of Evie's pulse oximeter exceeds FDA guidelines. This milestone underscores the company's objective to achieve FDA clearance for the Evie Med Ring, a medical-grade version of the wearable. The Evie Med Ring aims to provide a seamless blend of accessibility, personalization, and medical reliability, significantly differentiating itself from existing wellness solutions.
In addition to its technological advancements, Movano Health recently secured a strategic investment from a tier-one multi-billion dollar medical device company. This partnership, along with a $24 million capital raise, ensures financial stability and accelerates the commercialization of Movano's proprietary technologies. The company has also entered into agreements to explore future collaborations for the development and commercialization of their healthcare solutions.
Movano Health's commitment to innovation extends to strategic collaborations with prestigious institutions like MIT. The company’s Evie Ring is being utilized in the MAESTRO study to understand long COVID and chronic Lyme disease, providing continuous, reliable data that could reshape approaches to these debilitating conditions.
For more information on Movano Health and their latest updates, visit here.
Movano Inc. (NASDAQ: MOVE), operating as Movano Health, will report its first quarter 2023 financial and operating results on May 15, 2023. Management will host a conference call at 9:00 a.m. PDT (12:00 p.m. EDT) to discuss these results and provide a business update.
The company focuses on developing healthcare solutions that merge medical-grade data with consumer health devices to empower users in managing their health. Their product, the Evie Ring, aimed specifically at women's health, is set to launch in summer 2023. Interested parties can access the live webcast or conference call through the company’s investor relations website.
Movano Health (Nasdaq: MOVE) reported its Q4 and full-year 2022 financial results, revealing a net loss of $7.9 million for Q4, compared to $6.3 million in Q4 2021. For the year, the net loss was $30.3 million, consistent with the previous year. The company is preparing for the summer 2023 launch of its first product, the Evie Ring, and is conducting beta tests with multiple partners. Movano Health has filed for FDA clearance and has received nine new U.S. patents for its non-invasive monitoring technologies. The company ended 2022 with $10.8 million in cash. Additionally, it raised $7.5 million in a recent public offering to support product development.
Movano Health (NASDAQ: MOVE) has secured three new patents for its radio frequency (RF) technology aimed at enhancing health monitoring capabilities. The newly issued patents increase Movano's intellectual property portfolio to 21 patents issued and 38 pending. Notably, these patents focus on monitoring critical health metrics such as blood glucose levels, blood pressure, and heart rate. The proprietary System-on-a-Chip (SoC) allows for improved accuracy and compact device design. The SoC is set for clinical testing in March 2023, with future integration planned for Movano's wearables.